EA200970233A1 - Кандидатные агенты против инфекций - Google Patents
Кандидатные агенты против инфекцийInfo
- Publication number
- EA200970233A1 EA200970233A1 EA200970233A EA200970233A EA200970233A1 EA 200970233 A1 EA200970233 A1 EA 200970233A1 EA 200970233 A EA200970233 A EA 200970233A EA 200970233 A EA200970233 A EA 200970233A EA 200970233 A1 EA200970233 A1 EA 200970233A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- host
- response against
- candidate agents
- agents against
- against infections
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000001681 protective effect Effects 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010033078 Otitis media Diseases 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 208000025255 bacterial arthritis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
Abstract
Настоящее изобретение относится к применению плазминогена/плазмина и их производных в качестве агентов, усиливающих защитную реакцию хозяина против инфекции или других инфекционных заболеваний. Изобретение также относится к способу скрининга соединений, которые усиливают защитную реакцию хозяина против инфекции, путем оценки защитной реакции хозяина против бактериального артрита и спонтанного отита среднего уха на животной модели.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82366506P | 2006-08-28 | 2006-08-28 | |
PCT/SE2007/050585 WO2008026999A2 (en) | 2006-08-28 | 2007-08-28 | Candidates against infection |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970233A1 true EA200970233A1 (ru) | 2009-08-28 |
EA016250B1 EA016250B1 (ru) | 2012-03-30 |
Family
ID=39136397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970233A EA016250B1 (ru) | 2006-08-28 | 2007-08-28 | Применение плазминогена для лечения инфекционных заболеваний |
Country Status (12)
Country | Link |
---|---|
US (3) | US8318661B2 (ru) |
EP (1) | EP2056864B1 (ru) |
JP (1) | JP5566105B2 (ru) |
KR (1) | KR101517626B1 (ru) |
CN (2) | CN101573134B (ru) |
AU (1) | AU2007290881B2 (ru) |
CA (1) | CA2662101C (ru) |
DK (1) | DK2056864T3 (ru) |
EA (1) | EA016250B1 (ru) |
ES (1) | ES2451015T3 (ru) |
MX (1) | MX2009002226A (ru) |
WO (1) | WO2008026999A2 (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
KR20120050442A (ko) | 2009-07-10 | 2012-05-18 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민의 변이체 |
ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
ES2645509T3 (es) * | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
CA2823491A1 (en) | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
RU2020120075A (ru) | 2014-05-02 | 2020-07-03 | Кью Байолоджикс Инк. | Противомикробная иммуномодуляция |
TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
EP3391901B1 (en) * | 2015-12-18 | 2023-07-05 | Talengen International Limited | Plasminogen for use in treating liver tissue damage |
US11400142B2 (en) | 2015-12-18 | 2022-08-02 | Talengen International Limited | Treatment of diabetic nerve injury comprising administering plasminogen |
CN106890321A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
CN108463240A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
DK3391902T3 (da) | 2015-12-18 | 2023-11-20 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
EP3395355A4 (en) * | 2015-12-18 | 2019-06-12 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING CERVICAL EROSION |
WO2017101873A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
EP3395354B1 (en) * | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
CA3046666A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating tissue and organ fibrosis |
TWI684459B (zh) | 2016-12-15 | 2020-02-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療動脈粥樣硬化及其併發症的方法 |
US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
TW201829448A (zh) | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
EP3556384B1 (en) | 2016-12-15 | 2024-04-10 | Talengen International Limited | Plasminogen for use in treating diabetes |
CN108210895A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防动脉粥样硬化及其并发症的药物及其用途 |
WO2018107689A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂质肾损伤的方法 |
CA3047171A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating pathological renal tissue injury |
WO2018233604A1 (zh) | 2017-06-19 | 2018-12-27 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
TW201904990A (zh) * | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
CN107496911A (zh) * | 2017-10-20 | 2017-12-22 | 滕敏子 | 一种外科手术后用于防肿胀、抗感染的愈合剂 |
CN113164564A (zh) * | 2018-11-19 | 2021-07-23 | 诺尔玛克Ip股份有限公司 | 用于治疗或预防心内膜炎的安克洛酶 |
CN111742887A (zh) * | 2019-12-19 | 2020-10-09 | 广西医科大学第一附属医院 | 放疗后分泌性中耳炎树鼩模型的建立方法 |
WO2021160092A1 (zh) * | 2020-02-11 | 2021-08-19 | 泰伦基国际有限公司 | 一种治疗病毒性肺炎的方法和药物 |
WO2021180068A1 (zh) * | 2020-03-09 | 2021-09-16 | 泰伦基国际有限公司 | 一种治疗2019新型冠状病毒引发疾病的方法和药物 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN115845036B (zh) * | 2023-02-20 | 2023-05-09 | 滨州益洁口腔有限公司 | 用于口腔种植体牙龈组织的蛋白酶及制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3023143A (en) * | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5792835A (en) | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
US5397578A (en) * | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
US6420622B1 (en) * | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
WO2000004941A1 (en) | 1998-07-24 | 2000-02-03 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
WO2000051538A1 (en) | 1999-03-01 | 2000-09-08 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
AU2002365408B2 (en) | 2001-11-26 | 2008-04-24 | Genentech, Inc. | Catheter composition and uses thereof |
CA2475277A1 (en) | 2002-02-06 | 2003-08-14 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Method for producing recombinant proteins in micro-organisms |
CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK-5的制备方法 |
AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
-
2007
- 2007-08-28 WO PCT/SE2007/050585 patent/WO2008026999A2/en active Application Filing
- 2007-08-28 CA CA2662101A patent/CA2662101C/en not_active Expired - Fee Related
- 2007-08-28 EA EA200970233A patent/EA016250B1/ru not_active IP Right Cessation
- 2007-08-28 ES ES07794195.3T patent/ES2451015T3/es active Active
- 2007-08-28 CN CN2007800324051A patent/CN101573134B/zh active Active
- 2007-08-28 JP JP2009526572A patent/JP5566105B2/ja not_active Expired - Fee Related
- 2007-08-28 MX MX2009002226A patent/MX2009002226A/es active IP Right Grant
- 2007-08-28 EP EP07794195.3A patent/EP2056864B1/en not_active Not-in-force
- 2007-08-28 CN CN200780032092XA patent/CN101563100B/zh active Active
- 2007-08-28 KR KR1020097005738A patent/KR101517626B1/ko active IP Right Grant
- 2007-08-28 AU AU2007290881A patent/AU2007290881B2/en not_active Ceased
- 2007-08-28 DK DK07794195.3T patent/DK2056864T3/en active
- 2007-08-28 US US12/439,517 patent/US8318661B2/en active Active
-
2012
- 2012-11-26 US US13/685,466 patent/US20130149321A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,481 patent/US10729750B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK2056864T3 (en) | 2014-03-10 |
CN101563100A (zh) | 2009-10-21 |
US20160243204A1 (en) | 2016-08-25 |
MX2009002226A (es) | 2009-09-07 |
ES2451015T3 (es) | 2014-03-26 |
US20100099600A1 (en) | 2010-04-22 |
US8318661B2 (en) | 2012-11-27 |
JP5566105B2 (ja) | 2014-08-06 |
EP2056864B1 (en) | 2013-12-11 |
US10729750B2 (en) | 2020-08-04 |
AU2007290881A1 (en) | 2008-03-06 |
CN101563100B (zh) | 2013-08-07 |
EP2056864A2 (en) | 2009-05-13 |
AU2007290881B2 (en) | 2013-03-07 |
US20130149321A1 (en) | 2013-06-13 |
WO2008026999A2 (en) | 2008-03-06 |
EP2056864A4 (en) | 2012-01-25 |
WO2008026999A3 (en) | 2008-05-22 |
CN101573134B (zh) | 2013-03-06 |
CN101573134A (zh) | 2009-11-04 |
CA2662101C (en) | 2015-07-07 |
EA016250B1 (ru) | 2012-03-30 |
JP2010502600A (ja) | 2010-01-28 |
KR20090059122A (ko) | 2009-06-10 |
KR101517626B1 (ko) | 2015-05-07 |
CA2662101A1 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970233A1 (ru) | Кандидатные агенты против инфекций | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
CR20120356A (es) | Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
CY1110835T1 (el) | Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c | |
ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
EA200601391A1 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
RS52743B (en) | (2S, 3R) -N- (2 - ((3-PYRIDINYL) METHYL) -1-AZABICYCLO [2.2.2] OCT-3-IL) BENZOFURAN-2-CARBOXAMID, NEW FORMS OF SALTS AND PROCEDURES FOR THEIR USE | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
NO20074037L (no) | Farmasoytiske formuleringer med vedvarende frigivelse | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
RS54217B1 (en) | SOME TRIAZOLOPIRAZINS, THEIR COMPOSITIONS AND THE METHODS OF USING THEM | |
EA200700286A1 (ru) | Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов | |
CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
ATE420639T1 (de) | Antimykotische mittel | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
MEP15908A (en) | 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics | |
EA201000329A1 (ru) | Циклические депсипептиды | |
ATE412649T1 (de) | Substituierte heteroarylbenzofuransäuren | |
MA31567B1 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
EA200800070A1 (ru) | Производные 2-(1h-индолилсульфанил)ариламина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |